<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889510</url>
  </required_header>
  <id_info>
    <org_study_id>LIRALUNG</org_study_id>
    <nct_id>NCT02889510</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lecube, Albert, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynamic Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lecube, Albert, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with
      glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and
      the GLP-1 receptor has been found in significant amounts in the lung, it could be
      hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced
      pulmonary function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is growing evidence to suggest an association between type 2 diabetes and impaired
      pulmonary function. In this regard, several cross-sectional studies have appeared showing
      decreased indices of forced expiration, lung volume and diffusion capacity as the main lung
      dysfunctions detected in type 2 diabetic populations. In fact, diabetes is frequently
      co-morbid with chronic obstructive pulmonary disease, and data from the Atherosclerosis Risk
      in Communities Study showed a faster pulmonary function decline in type 2 diabetic patients
      than in other participants. This is important because the reduction of FEV1 has been
      demonstrated an independent cause of mortality in diabetic patients.

      Interestingly, lung function measures start to decrease several years before the diagnosis of
      diabetes. In this regard an investigation found that insulin resistance is an independent
      determinant of pulmonary function in non-diabetic morbidly obese women. In addition, the
      results suggest that the metabolic pathways related to insulin resistance are crucial in
      initiating lung abnormalities in type 2 diabetic patients.

      The reasons for the association between respiratory disease and diabetes are unclear.
      However, the relationship between type 2 diabetes and muscle strength, the impairment in lung
      elastic properties, and the presence of a low-grade chronic inflammation state are involved.
      In supporting these findings, thickening of the alveolar epithelia and pulmonary capillary
      basal lamina, fibrosis, centrilobular emphysema, and pulmonary microangiopathy have been
      detected in autopsies of diabetic patients. In addition, defects in the bronchiolar
      surfactant layer, which is involved in maintaining airway stability and diameter, may also be
      considered a contributing factor to the impairment of airway calibre regulation in diabetic
      patients. When the alveolocapillary barrier is damaged, surfactant proteins leak into the
      bloodstream. A recent population-based random sample study has described how increased
      circulating levels of surfactant protein A, the major surfactant-associated protein, were
      associated with altered glucose tolerance and insulin resistance. Therefore, surfactant
      defects in diabetic individuals may also lead to an increase in airway resistance and to a
      reduction in ventilatory patterns as observed in our studies. In addition, as experimental
      studies have shown that glucagon-like peptide 1 plays a role in the stimulation of surfactant
      production, its underlying deficit in type 2 diabetes could also enhance the airway
      resistance observed in these patients. However, the beneficial effects on pulmonary function
      using incretin-based therapies remain to be elucidated.

      Clinical trial study hypothesis is that treatment with an incretin mimetic such as
      liraglutide may ameliorate lung function parameters in type 2 diabetics patients,
      independently of weight reduction. This hypothesis is based on the following factors:

        1. - There is growing evidence to suggest an association between type 2 diabetes and
           impaired pulmonary function.

        2. - In patients with type 2 diabetes, the incretin effect is severely reduced or absent,
           contributing to the reduced lung function parameters observed in type 2 diabetic
           patients.

        3. - GLP-1 stimulates surfactant production in &quot;in vitro&quot; studies and, in consequence, the
           increase in surfactant production induced by liraglutide could be the main factor
           involved in the respiratory improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in serum levels of surfactant A and D protein.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline in serum levels of surfactant A and D protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by residual volume (RV)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by residual volume (RV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7-week subcutaneous liraglutide treatment once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7-week subcutaneous placebo treatment once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>7-week subcutaneous liraglutide once daily</description>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>7-week subcutaneous placebo once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Subjects between 40 and 65 years old. Diagnosis of type 2 diabetes mellitus with more
             than 5 years of evolution of disease.

          -  Metformin (alone or in combination with sulfonylurea and / or insulin and / or
             thiazolidinediones) at a stable dose for at least the past 3 months.

          -  HbA1c ≥ 7,0 y ≤ 9,0 %.

          -  BMI between 30 and 40 kg / m2.

          -  No pulmonary disease (COPD, asthma, fibrosis, etc) known.

          -  Baseline FEV1 decline of equal or greater than 10% in the percentage of the
             theoretical value.

          -  Chest radiography without significant changes in the lung parenchyma

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Treatment with inhibitors of dipeptidyl peptidase 4 glitazones and / or

          -  SGLT2 inhibitors.

          -  Active and former smokers for less than five years ago smoking.

          -  Chronic obstructive pulmonary disease.

          -  Respiratory sleep disorders that require treatment with continuous positive pressure
             in the airway.

          -  Asthma treatment with bronchodilators.

          -  Previous bariatric surgery.

          -  Cardiovascular disease, heart failure and / or stroke.

          -  Pathology of the chest wall.

          -  Serum creatinine&gt; 1.7 mg / dl.

          -  Abnormal results in liver function test (Alanine transaminase/ Aspartate
             Aminotransferase greater than twice the upper limit of normal).

          -  History of acute or chronic pancreatitis.

          -  Personal or family history of medullary thyroid cancer or Multiple

          -  Endocrine Neoplasia (MEN ) type 2.

          -  Active neoplasms or neoplastic patients considered disease-free history from less than
             5 years ago.

          -  Women of childbearing age who are pregnant (positive pregnancy test within 14 days
             before the start of treatment) or intend to get pregnant.

          -  Lactating women.

          -  Women of childbearing potential not using adequate contraception (such as oral
             contraceptives, intrauterine device or barrier method of birth control along with
             spermicide or surgical sterilization) or unwilling to use during the study (as
             required by local laws or practices).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Lecube, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitari Arnau de Vilanova de Lleida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raúl Montalbán Casado</last_name>
    <phone>+34 914561105</phone>
    <email>raul.m@dynasolutions.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liana De Plasencia</last_name>
    <phone>+34 914561105</phone>
    <email>l.plasencia@dynasolutions.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Puig-Domingo</last_name>
      <phone>+34 934978653</phone>
      <email>mpuig.germanstrias@gencat.cat</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Pellitero</last_name>
      <phone>+34 625391561</phone>
      <email>spellitero.germanstrias@gencat.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Silvia Pellitero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Salvador</last_name>
      <phone>+34 660597980</phone>
      <email>jsalvador@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafael Simó</last_name>
      <email>rafael.simo@vhir.org</email>
    </contact>
    <contact_backup>
      <last_name>Lorena Ramos</last_name>
      <phone>+34 934894198</phone>
      <email>lorena.ramos@vhir.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Ciudín</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Lecube, PhD</last_name>
      <phone>+34 973705183</phone>
      <email>alecube@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Martí</last_name>
      <email>rmarti@irblleida.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Carolina López</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Turino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asunción Seminario</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Tinahones</last_name>
      <phone>+34 951034016</phone>
      <email>fjtinahones@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Inmaculada Picón</last_name>
      <phone>+34 638430738</phone>
      <email>ipiconcesar@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Baldomera Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paloma Romero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Pablo García</last_name>
      <phone>+34 607686901</phone>
      <email>garcialunapp@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Ortega</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Jesús Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2000 Oct;50(2):153-9.</citation>
    <PMID>10960726</PMID>
  </reference>
  <reference>
    <citation>Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, Selvin E, Brancati FL. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2008 Apr;31(4):741-6. Epub 2007 Dec 4.</citation>
    <PMID>18056886</PMID>
  </reference>
  <reference>
    <citation>Vara E, Arias-Díaz J, Garcia C, Balibrea JL, Blázquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001 Mar;163(4):840-6.</citation>
    <PMID>11282754</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Muñoz X, Lloberes P, Hernández C, Simó R. Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study. Diabetes Metab Res Rev. 2010 Nov;26(8):639-45. doi: 10.1002/dmrr.1131. Epub 2010 Sep 29.</citation>
    <PMID>20882512</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Muñoz X, Hernández C, Mesa J, Simó R. Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study. Diabetologia. 2010 Jun;53(6):1210-6. doi: 10.1007/s00125-010-1700-5. Epub 2010 Mar 9.</citation>
    <PMID>20217039</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Lloberes P, Romero O, Mesa J, Hernández C, Simó R. Diabetes is an independent risk factor for severe nocturnal hypoxemia in obese patients. A case-control study. PLoS One. 2009;4(3):e4692. doi: 10.1371/journal.pone.0004692. Epub 2009 Mar 5.</citation>
    <PMID>19262746</PMID>
  </reference>
  <reference>
    <citation>Fernández-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, Ricart W. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care. 2008 May;31(5):958-63. doi: 10.2337/dc07-2173. Epub 2008 Feb 19.</citation>
    <PMID>18285549</PMID>
  </reference>
  <reference>
    <citation>Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008 Oct;32(4):962-9. doi: 10.1183/09031936.00012408. Epub 2008 Jun 25.</citation>
    <PMID>18579551</PMID>
  </reference>
  <reference>
    <citation>Davis WA, Knuiman M, Kendall P, Grange V, Davis TM; Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004 Mar;27(3):752-7.</citation>
    <PMID>14988297</PMID>
  </reference>
  <reference>
    <citation>Nicolaie T, Zăvoianu C, Nuţă P. Pulmonary involvement in diabetes mellitus. Rom J Intern Med. 2003;41(4):365-74. Review.</citation>
    <PMID>15526520</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>liraglutide</keyword>
  <keyword>lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

